Skip to main content
. Author manuscript; available in PMC: 2022 Apr 2.
Published in final edited form as: Biofabrication. 2021 Apr 2;13(3):10.1088/1758-5090/abd9d9. doi: 10.1088/1758-5090/abd9d9

Figure 5.

Figure 5.

Safranin-O staining and immunohistochemistry of human neocartilage derived from donors 2 and 3. (a) Safranin-O staining, (b) type II collagen, and (c) type I collagen of neocartilage constructs derived from P5 and P9 donor 2 hACs, and from P3, P7, and P11 donor 3 hACs. The effects of no treatment (Ctrl), and aggregate rejuvenation followed by TCL treatment (Agg+TCL) on human neocartilage are shown.